Biology:CD160

From HandWiki
Short description: Protein-coding gene in the species Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

CD160 antigen is a protein that in humans is encoded by the CD160 gene.[1][2][3]

CD160 is a 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich, glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells, spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16+ cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab+CD8brightCD95+CD56+CD28-CD27-cells. In tissues, CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules.[3]

Clinical significance

CD160 is a ligand for HVEM, and considered a proposed immune checkpoint inhibitor with anti-cancer activity along with anti- PD-1 antibodies.[4] CD160 has also been proposed as a potential new target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs.[5]

Related gene problems

See also

References

  1. "Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes". J Immunol 161 (6): 2780–90. Oct 1998. doi:10.4049/jimmunol.161.6.2780. PMID 9743336. 
  2. "Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells". J Immunol 162 (3): 1223–6. Apr 1999. doi:10.4049/jimmunol.162.3.1223. PMID 9973372. 
  3. 3.0 3.1 "Entrez Gene: CD160 CD160 molecule". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=11126. 
  4. Stecher, Carmen; Battin, Claire; Leitner, Judith; Zettl, Markus; Grabmeier-Pfistershammer, Katharina; H?ller, Christoph; Zlabinger, Gerhard J.; Steinberger, Peter (22 May 2017). "PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells". Frontiers in Immunology 8: 572. doi:10.3389/fimmu.2017.00572. PMID 28588576. 
  5. Chabot, Sophie; Jabrane-Ferrat, Nabila; Bigot, Karine; Tabiasco, Julie; Provost, Alexandra; Golzio, Muriel; Noman, Muhammad Zaeem; Giustiniani, J?r?me et al. (9 May 2011). "A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor". The Journal of Experimental Medicine 208 (5): 973–986. doi:10.1084/jem.20100810. PMID 21482699. 
  6. "Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome". Am. J. Hum. Genet. 80 (2): 232–40. February 2007. doi:10.1086/510919. PMID 17236129. 

Further reading

External links